CARDIOVASCULAR DISEASE: PCSK9 inhibition: a new player in cholesterol-lowering therapies?

    loading  Checking for direct PDF access through Ovid


The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed.

Refers to Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017)

Related Topics

    loading  Loading Related Articles